文章：

尼拉帕尼在her2阴性、brca突变、可切除乳腺癌患者中的新辅助研究

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer 

原文发布日期：2022-07-04 

英文摘要：

This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed. 

摘要翻译：

单臂小研究（NCT03329937）评估了替尼帕比姆作为新辅助治疗对局部HER2负性、BRCA突变阳性的乳腺癌患者的抗肿瘤活性及其安全性。共21名患者接受每日一次的替尼帕比姆200 mg，每次给药周期为28天。在第2个周期结束后，通过MRI测量的肿瘤反应率为90.5%（完全反应），其中接受单一替尼帕比姆（2至6周期）治疗的15名患者中有40.0%（共6名）出现病理学上完全反应；未发现任何新的安全信号。观察到替尼帕比姆在肿瘤内部的高浓度。 

原文链接：

https://www.nature.com/articles/s43018-022-00400-2